Literature DB >> 23966509

Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.

Marit Gaastra Maaland1, Mark G Papich, John Turnidge, Luca Guardabassi.   

Abstract

Doxycycline is a tetracycline that has been licensed for veterinary use in some countries, but no clinical breakpoints are available for veterinary pathogens. The objectives of this study were (i) to establish breakpoints for doxycycline and (ii) to evaluate the use of tetracycline as a surrogate to predict the doxycycline susceptibility of Staphylococcus pseudintermedius isolates. MICs and inhibition zone diameters were determined for 168 canine S. pseudintermedius isolates according to Clinical and Laboratory Standards Institute (CLSI) standards. Tetracycline resistance genes were detected by PCR, and time-kill curves were determined for representative strains. In vitro pharmacodynamic and target animal pharmacokinetic data were analyzed by Monte Carlo simulation (MCS) for the development of MIC interpretive criteria. Optimal zone diameter breakpoints were defined using the standard error rate-bounded method. The two drugs displayed bacteriostatic activity and bimodal MIC distributions. Doxycycline was more active than tetracycline in non-wild-type strains. MCS and target attainment analysis indicated a certainty of ≥ 90% for attaining an area under the curve (AUC)/MIC ratio of >25 with a standard dosage of doxycycline (5 mg/kg of body weight every 12 h) for strains with MICs of ≤ 0.125 μg/ml. Tetracycline predicted doxycycline susceptibility, but current tetracycline breakpoints were inappropriate for the interpretation of doxycycline susceptibility results. Accordingly, canine-specific doxycycline MIC breakpoints (susceptible, ≤ 0.125 μg/ml; intermediate, 0.25 μg/ml; resistant, ≥ 0.5 μg/ml) and zone diameter breakpoints (susceptible, ≥ 25 mm; intermediate, 21 to 24 mm; resistant, ≤ 20 mm) and surrogate tetracycline MIC breakpoints (susceptible, ≤ 0.25 μg/ml; intermediate, 0.5 μg/ml; resistant, ≥ 1 μg/ml) and zone diameter breakpoints (susceptible, ≥ 23 mm; intermediate, 18 to 22 mm; resistant, ≤ 17 mm) were proposed based on the data generated in this study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23966509      PMCID: PMC3889732          DOI: 10.1128/JCM.01498-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.

Authors:  Gunnar Kahlmeter; Derek F J Brown; Fred W Goldstein; Alasdair P MacGowan; Johan W Mouton; Anders Osterlund; Arne Rodloff; Martin Steinbakk; Pavla Urbaskova; Alkiviadis Vatopoulos
Journal:  J Antimicrob Chemother       Date:  2003-07-01       Impact factor: 5.790

2.  Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs.

Authors:  M Barza; R B Brown; C Shanks; C Gamble; L Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

3.  Pharmacokinetics of doxycycline in dogs.

Authors:  R C Wilson; D T Kemp; J V Kitzman; D D Goetsch
Journal:  Can J Vet Res       Date:  1988-01       Impact factor: 1.310

4.  The disposition of doxycyline by man and dog.

Authors:  M Schach von Wittenau; T M Twomey
Journal:  Chemotherapy       Date:  1971       Impact factor: 2.544

5.  Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.

Authors:  I Chopra; M Roberts
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

6.  Comparison of antimicrobial resistance phenotypes and resistance genes in Enterococcus faecalis and Enterococcus faecium from humans in the community, broilers, and pigs in Denmark.

Authors:  F M Aarestrup; Y Agerso; P Gerner-Smidt; M Madsen; L B Jensen
Journal:  Diagn Microbiol Infect Dis       Date:  2000-06       Impact factor: 2.803

7.  Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.

Authors:  Ronald N Jones; Matthew G Stilwell; Michael L Wilson; Rodrigo E Mendes
Journal:  Diagn Microbiol Infect Dis       Date:  2013-03-13       Impact factor: 2.803

8.  [Doxycycline: pharmacokinetics and suggested dosage in dogs and cats].

Authors:  F J van Gool; C Santoul; A M Giuseppin-Huet
Journal:  Tijdschr Diergeneeskd       Date:  1988-11-01

9.  Comparative pharmacokinetics of doxycycline in cats and dogs.

Authors:  J L Riond; S L Vaden; J E Riviere
Journal:  J Vet Pharmacol Ther       Date:  1990-12       Impact factor: 1.786

10.  Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs.

Authors:  Tara L Bidgood; Mark G Papich
Journal:  Am J Vet Res       Date:  2003-08       Impact factor: 1.156

View more
  14 in total

1.  In Vitro Antimicrobial Susceptibility of Staphylococcus pseudintermedius Isolates of Human and Animal Origin.

Authors:  Romney M Humphries; Max T Wu; Lars F Westblade; Amy E Robertson; Carey-Ann D Burnham; Meghan A Wallace; Eileen M Burd; Sara Lawhon; Janet A Hindler
Journal:  J Clin Microbiol       Date:  2016-03-09       Impact factor: 5.948

Review 2.  A Critical Review of the Pharmacokinetics, Pharmacodynamics, and Safety Data of Antibiotics in Avian Species.

Authors:  Hui Yun Soh; Prisca Xin Yi Tan; Tao Tao Magdeline Ng; Hui Ting Chng; Shangzhe Xie
Journal:  Antibiotics (Basel)       Date:  2022-05-31

3.  Direct repeat unit (dru) typing and antimicrobial resistance of methicillin-resistant Staphylococcus pseudintermedius isolated from dogs in Atlantic Canada.

Authors:  Matthew E Saab; J Scott Weese; J T McClure
Journal:  Can J Vet Res       Date:  2017-07       Impact factor: 1.310

4.  High genotypic diversity among methicillin-resistant Staphylococcus pseudintermedius isolated from canine infections in Denmark.

Authors:  Peter Damborg; Arshnee Moodley; Bent Aalbæk; Gianpiero Ventrella; Teresa Pires Dos Santos; Luca Guardabassi
Journal:  BMC Vet Res       Date:  2016-06-29       Impact factor: 2.741

5.  Considerations for using minocycline vs doxycycline for treatment of canine heartworm disease.

Authors:  Mark G Papich
Journal:  Parasit Vectors       Date:  2017-11-09       Impact factor: 3.876

Review 6.  En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.

Authors:  Pierre-Louis Toutain; Alain Bousquet-Mélou; Peter Damborg; Aude A Ferran; Dik Mevius; Ludovic Pelligand; Kees T Veldman; Peter Lees
Journal:  Front Microbiol       Date:  2017-12-15       Impact factor: 5.640

7.  Antimicrobial synergy between carprofen and doxycycline against methicillin-resistant Staphylococcus pseudintermedius ST71.

Authors:  Rikke Prejh Brochmann; Alexandra Helmfrid; Bimal Jana; Zofia Magnowska; Luca Guardabassi
Journal:  BMC Vet Res       Date:  2016-06-24       Impact factor: 2.741

8.  The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis.

Authors:  Zhixin Lei; Qianying Liu; Bing Yang; Saeed Ahmed; Jiyue Cao; Qigai He
Journal:  Oncotarget       Date:  2017-12-07

9.  In vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by cefazolin, cefovecin, doxycycline and pradofloxacin over a range of bacterial densities.

Authors:  Joseph M Blondeau; Shantelle D Fitch
Journal:  Vet Dermatol       Date:  2020-02-06       Impact factor: 1.589

10.  Population Pharmacokinetics of Doxycycline in Children.

Authors:  Elizabeth J Thompson; Huali Wu; Chiara Melloni; Stephen Balevic; Janice E Sullivan; Matthew Laughon; Kira M Clark; Rohit Kalra; Susan Mendley; Elizabeth H Payne; Jinson Erinjeri; Casey E Gelber; Barrie Harper; Michael Cohen-Wolkowiez; Christoph P Hornik
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.